Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets - Form 6-K
Evotec SE: Bayer discontinues clinical development candidate eliapixant , Evotec regains the rights to all P2X3 assets Hamburg, Germany - Evotec SE announces today that the... | February 4, 2022